Estrogen action in the reproductive tract of rhesus monkeys during antiprogestin treatment
- 1 April 1993
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 132 (4) , 1845-1856
- https://doi.org/10.1210/en.132.4.1845
Abstract
We previously reported that RU486 can reverse progesterone (P)-induced suppression of the estrogen receptor (ER) in the uterus of pregnant rhesus monkeys, but we did not determine whether estrogen (E) could act through its receptor in the presence of P and RU486. To pursue this question, we treated spayed rhesus monkeys with various hormonal regimens and evaluated the effects of E in the oviduct and endometrium, with and without RU486 treatment, on ER and progestin receptor (PR) levels, morphology, apoptosis, and degree of proliferation. The latter was assessed immunocytochemically with a monoclonal antibody (Ki-67) against a nuclear antigen present only in proliferating cells. Animals were treated for 2 weeks with 17beta-estradiol (E2) and then for 2 weeks with E2 Plus P to produce a regressed oviduct and a secretory endometrium. The animals were then treated for 2 more weeks with four different treatments, as follows: 1) E2, P, and vehicle; II) E2 and vehicle; III) E2, P, and RU486; and IV) E2 and RU486 (n = 4 each). In group I, menstruation did not occur, and the endometrium exhibited stromal cell enlargement, extensive development of the spiral arteries, few Ki-67-positive cells, and low levels of ER and PR. Oviducts in group I remained regressed, Ki-67-positive epithelial cells were few, and levels of ER and PR were low. In contrast, in groups II, III, and IV, the oviducts had responded to E2 and were fully ciliated and secretory, with elevated levels of ER and nuclear PR. All animals in these three groups menstruated and then regenerated their endometrium. The regenerated endometria expressed elevations in ER, nuclear PR, and epithelial Ki-67 index. However, the endometria of RU486-treated monkeys in groups III and IV had significantly more epithelial cell death by apoptosis, increased stromal cell compaction, and fewer Ki-67-positive stromal cells than in the E2 controls (group II). In group IV, RU486 caused a significant decrease in endometrial weight. Thus, RU486 blocked P action and allowed E2 to act in a normal fashion in the oviduct and endometrium on several end points, but it also had antiproliferative effects that opposed E2 action, especially in the endometrium.This publication has 23 references indexed in Scilit:
- Differential suppression of progesterone receptors by progesterone in the reproductive tract of female macaquesJournal of Steroid Biochemistry, 1986
- The Antiprogestin RU38 486: Receptor-Mediated ProgestinVersusAntiprogestin Actions Screened in Estrogen-Insensitive T47DCOHuman Breast Cancer Cells*Endocrinology, 1985
- RU486, A Progestin and Glucocorticoid Antagonist, Inhibits the Growth of Breast Cancer Cells via the Progesterone Receptor*Journal of Clinical Endocrinology & Metabolism, 1985
- Endometrial and Pituitary Responses to the Steroidal Antiprogestin RU 486in Postmenopausal WomenJournal of Clinical Endocrinology & Metabolism, 1985
- Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.The Journal of Immunology, 1984
- Induction of menstruation by an antiprogesterone steroid (RU 486) in primates: site of action, dose-response relationships, and hormonal effectsFertility and Sterility, 1983
- Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInternational Journal of Cancer, 1983
- Monoclonal antibodies to human estrogen receptor.Proceedings of the National Academy of Sciences, 1980
- Hormonal control of apoptosis in hamster uterine luminal epitheliumJournal of Anatomy, 1979
- A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acidBiochemical Journal, 1956